2-[[(2S)-1-(二(羧甲基)氨基)-3-[4-(2-羟基乙基硫代氨基甲酰氨基)苯基]丙-2-基]-(羧甲基)氨基]乙酸 | 128817-30-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-[[(2S)-1-(二(羧甲基)氨基)-3-[4-(2-羟基乙基硫代氨基甲酰氨基)苯基]丙-2-基]-(羧甲基)氨基]乙酸
• 英文名称: Eotube
• 英文别名: 2-[[(2S)-2-[bis(carboxymethyl)amino]-3-[4-(2-hydroxyethylcarbamothioylamino)phenyl]propyl]-(carboxymethyl)amino]acetic acid
• CAS: 128817-30-1
• 化学式: C₂₀H₂₈N₄O₉S
• 分子量: 500.5
• InChiKey: PQYGLZAKNWQTCV-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  34
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  201
• 氢给体数：
  7
• 氢受体数：
  13

文献信息

• [EN] ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT DES ANTICORPS ANTI-B7-H3
  申请人：INTOCELL INC

  公开号：WO2021260438A1

  公开（公告）日：2021-12-30

  The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

  本公开涉及抗体药物结合物（ADCs），其中一个或多个活性剂通过连接剂与抗B7-H3抗体结合。连接剂可能包括一个单位，将活性剂共价连接到抗体上。本公开进一步涉及特异性结合B7-H3的单克隆抗体和抗原结合片段、变体、多聚体版本或双特异性抗体，以及在各种治疗、诊断和预防适应症中制备和使用这些抗B7-H3抗体和抗原结合片段的方法。
• MitoNEET polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
  申请人：Colca R. Jerry

  公开号：US20050043361A1

  公开（公告）日：2005-02-24

  The invention relates generally to a family of polypeptides from mitochondrial membranes, which bind insulin sensitizing, antidiabetic thiazolodinediones, and nucleic acid sequences encoding the family of polypeptides. The invention relates to methods of identifying therapeutic agents that bind to the polypeptides of the present invention. The invention further relates to methods useful for treating or modulating metabolic disorders in mammals in need of such biological effect.

  本发明涉及来自线粒体膜的一系列多肽，它们能够结合胰岛素敏感、抗糖尿病的噻唑烷二酮类药物，以及编码该多肽家族的核酸序列。本发明涉及用于鉴定与本发明中多肽结合的治疗剂的方法。本发明还涉及用于治疗或调节需要此种生物效应的哺乳动物的代谢性疾病的方法。
• Improvements in or relating to modified haptens useful as imaging and therapeutic agents
  申请人：HYBRITECH INCORPORATED

  公开号：EP0327365A2

  公开（公告）日：1989-08-09

  The present invention discloses a method for modifying the pharmacokinetics of a hapten which is useful as an in vivo radioimaging or radiotherapeutic agent. Compositions comprising a derivatized hapten of the invention are provided for in vivo imaging and therapy. A compound of Formula (I): p-R1-C6H4-CH2-EDTA-M (I) wherein R1 is R2 is hydrogen, an amino group, -OC(̵Y), -p-phenyl-CH2-Y, an unsubstituted C1 to C30 branched or straight chain alkyl group; a substituted C1 to C30 branched or straight chain alkyl, cycloalkyl, aryl or arylalkyl group, in which the substituents are one or more of any of: hydroxy, carboxy, =O, =S, -S-, -SR4, fluoro, chloro, bromo, iodo, amino, nitro, -S03H, -NHR3, -NHR4, -N(R3)2, -CONHR3, -COOR3, -SO4, -PO4, phenyl, benzyl, imidazolo, or a group of the formulae: wherein R3 is hydrogen, a C1 to C30 straight or branched chain alkyl group, -p-phenyl-CH2-Y, or a non-reactive functional group; Y is EDTA, DTPA, DOTA, HETA, TRITA or TETA; R4 is H or and, M is a metal ion, or a pharmaceutically-acceptable salt thereof.

  本发明公开了一种改变合生元药代动力学的方法，该合生元可用作体内放射成像剂或放射治疗剂。提供了包含本发明衍生化合素的用于体内成像和治疗的组合物。式 (I) 的化合物： p-R1-C6H4-CH2-EDTA-M (I) 其中 R1 是 R2 是氢、氨基、-OC(̵Y)、-p-苯基- -Y、未取代的 C1 至 C30 支链或直链烷基；取代的 C1 至 C30 支链或直链烷基、环烷基、芳基或芳烷基，其中取代基是羟基、羧基、＝O、＝S 中的一个或多个、 -S-、-SR4、氟、氯、溴、碘、氨基、硝基、-S03H、-NHR3、-NHR4、-N(R3)2、-CONHR3、-COOR3、-SO4、-PO4、苯基、苄基、咪唑基或式中的一个基团： 其中 R3 为氢、C1-C30 直链或支链烷基、-p-苯基- -Y、 或非反应性官能团；Y 是 EDTA、DTPA、DOTA、HETA、TRITA 或 TETA；R4 是 H 或 M。 M 是金属离子或其药学上可接受的盐。
• Bifunctional chimeric antibodies
  申请人：HYBRITECH INCORPORATED

  公开号：EP0369566A2

  公开（公告）日：1990-05-23

  The present invention discloses novel biologically produced bifunctional chimeric antibodies, directed against human carcinoembryonic antigen and metal chelates, having two sets of antigen-specific variable regions of defined amino acid sequences. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are disclosed. Eukaryotic host cells capable of biological expression of the bifunctional chimeric antibodies and comprising the novel bifunctional chimeric antibody-encoding DNA constructs are also provided.

  本发明公开了针对人类癌胚抗原和金属螯合物的新型生物制造的双功能嵌合抗体，该抗体具有两组确定氨基酸序列的抗原特异性可变区。本发明公开了包含本发明新型抗体的轻链和重链可变区的 DNA 构建。还提供了能够生物表达双功能嵌合抗体并包含新型双功能嵌合抗体编码 DNA 构建体的真核宿主细胞。
• Chimeric antibodies directed against metal chelates
  申请人：HYBRITECH INCORPORATED

  公开号：EP0369567A2

  公开（公告）日：1990-05-23

  The present invention discloses novel chimeric monoclonal antibodies, directed against metal chelates of EDTA derivatives, having chelate-specific variable regions of defined amino acid sequences. DNA constructs for the eight and heavy chain variable regions com­prising the novel antibodies of the invention are provided. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also provided.

  本发明公开了针对 EDTA 衍生物金属螯合物的新型嵌合单克隆抗体，该抗体具有定义氨基酸序列的螯合物特异性可变区。本发明提供了包含本发明新型抗体的八链和重链可变区的 DNA 构建。还提供了能够表达嵌合抗体并包含新型嵌合抗体编码 DNA 构建体的真核宿主细胞。